Background Total knee replacement (TKR) or unicompartmental knee replacement (UKR) are options for end-stage osteoarthritis. However, comparisons between the two procedures are confounded by diff erences in baseline characteristics of patients undergoing either procedure and by insuffi cient reporting of endpoints other than revision. We aimed to compare adverse outcomes for each procedure in matched patients.
Introduction
Total knee replacement (TKR), usually undertaken for end-stage osteoarthritis, is one of the commonest surgical procedures, with more than 76 000 TKRs done every year in the UK. 1 International trends suggest that this number will rise substantially, largely because of the ageing population and an increased prevalence of risk factors, including obesity. 2 TKR is a highly successful and cost-eff ective procedure. In terms of implant survival, more than 95% are in situ 10 years after surgery.
1,3,4 However, implant survival is an imperfect measure. With this measure, patients who have died, those who undergo reoperations that are not regarded as revisions (such as debridement for infection or manipulation under anaesthetic for stiff ness), and those who have poorly functioning, but unrevised, knee replacements, are all classed as successes. 5 The proportion of TKRs that is judged successful changes with the use of diff erent outcome measures. 90-day mortality after TKR is 0·4%, 6 by 4 years, 3·8% of patients undergo a non-revision reoperation; 7 8·5% of patients have worse patient-reported outcome measures 6 months after knee replacement than they had beforehand; 8 and up to 20% are dissatisfi ed after TKR. 9 A large proportion of patients who are eligible for TKR are also eligible for unicompartmental knee replacement (UKR) in which only the parts of the knee aff ected by osteoarthritis are replaced. 10, 11 Better patient reported outcomes can be obtained with UKR than with TKR, and mortality and major complications are lower after UKR than after TKR. 4, 12 However, unadjusted data from national registries show a signifi cantly higher revision rate for UKR than for TKR. 1, 3, 4 Because revision rate has traditionally been regarded as the most important factor to determine implant choice, only 8% of knee replacements done each year in the UK are UKRs, and most knee surgeons do not do them.
As such, the use of UKR in the treatment of end-stage osteoarthritis is controversial. Fair comparison of TKR and UKR is hampered by diff erences in the baseline characteristics of patients being off ered each procedure The aim of this study was to comprehensively compare the rates of adverse outcomes after TKR and UKR, with large datasets from the National Joint Registry for England and Wales (NJR), Hospital Episode Statistics (HES), and the Offi ce for National Statistics (ONS). We have studied multiple outcomes, including complications, readmission, reoperation, and death.
Methods

Data source
We analysed NJR records linked to data from the HES database. The NJR began collecting data in 2003 and contains details of more than 1 million joint replacements, making it the largest joint registry in the world.
1 For this study, we extracted data for all knee replacements done between the start of data collection on April 1, 2003, and Aug 28, 2012. Where possible, we linked these data to corresponding records in the HES database. Records could be linked to HES if they took place in, or were funded by, an NHS trust in England. HES provides additional information for every patient (including detailed comorbidity information and deprivation indices), and about every procedure (including length of stay and need for blood transfusion or critical care). Additional linked records contain details of readmissions, reoperations, and revisions not recorded in the NJR database. Data for allcause mortality are provided by the ONS; these data are linked periodically to the NJR database. The data used here were extracted from the NJR shortly after the latest NJR-ONS linkage. Patients consent for their data to be collected from the NJR. The National Information Governance Board (now the Confi dentiality Advisory Group) gave us permission to link the datasets (application number ECC 1-02 (FT3)/2013). We consulted the National Research Ethics Service who confi rmed that we did not need local research ethics committee approval.
Procedures
We did analyses to compare the outcomes of TKR and UKR by six measures: rates of revision, revision/ reopera tion, and readmission; length of stay, complications of surgery, and mortality. To address the problem of confounding by indication, we have matched patients with propensity scoring techniques. We compared the reasons for revision (as reported by the operating surgeon) and the revision operation (exchange of modular components or secondary patellar resurfacing, conversion to primary TKR, complex revision) for the two procedures. Complex revisions were defi ned as revisions to hinged components or components with stems or wedges, or two-stage procedures. We restricted our analyses to patients older than 18 years undergoing primary knee replacement for osteoarthritis. We excluded patellofemoral replacements, so-called complex primary knee replacements, and primary operations with augmentation and stems (implying a complex deformity). We showed signifi cant diff erences in baseline characteri stics between groups (table 1).
Statistical analysis
We used propensity score matching to generate matched cohorts for comparison. 16 First, we estimated the eff ects of each confounder on treatment allocation using a logistic regression model. Using these estimates, we generated a score representing the probability of each knee receiving UKR; we matched three TKR patients to every one UKR patient on the basis of this propensity
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Hazard ratios less than 1 favour unicompartmental knee replacement. The revision/reoperation hazard ratios are split because of time-varying hazard (see text); survival and NNT are provided at 8 years. NNT=number needed to treat (ie, number of patients switching treatment to avoid one adverse event). TKR=total knee replacement. UKR=unicompartmental knee replacement. *Hazard ratios are provided for mortality (Cox regression). †Subhazard ratios are provided for revision and revision/reoperation (competing risks regression). , and the grade of the primary surgeon (consultant or trainee). Bodymass index (BMI) had a large proportion of missing data and, we therefore did not include it in the propensity score analysis. As a sensitivity analysis, we calculated estimates for complete case datasets, with and without BMI, and after completing the missing values using multiple imputation (appendix). We used proportional hazards regression to examine survival outcomes (revision, revision/reoperation, and mortality). Because mortality can be regarded as a competing risk for revision surgery, we used competing risk regression when examining revision and revision/ reoperation; 17 we used Cox regression for the mortality comparison. We examined continuous outcomes (length of stay) using linear regression and binary outcomes (complications during the primary admission) using logistic regression, and examined readmission rate (within the fi rst year) using a zero-infl ated Poisson model.
For the survival models, we tested the proportional hazards assumption using Schoenfeld's residuals. If the proportional hazards assumption was violated, we analysed survival hazards in sections, with breaks being placed at the points of divergence from proportionality. Results of these models are presented as overall survival percentages, hazard ratios, and numbers needed to treat (NNT, representing the number needing to switch from one procedure to the other to avoid one adverse event, calculated with Altman and colleagues' 18 method). We used Stata (version 12.1) for all statistical analyses, and used R (R Foundation for Statistical Computing, Vienna, Austria) to do the matching on the basis of propensity score.
Role of the funding source
The sponsors of the study had no role in the design or conduct of the study. All authors had full access to the data and take responsibility for the contents of the study and the decision to proceed to publication. DWM is the guarantor.
Results
From a pool of 552 015 records from the NJR, and after exclusion of patellofemoral and complex primary knee replacements, a total of 341 749 records (315 767 TKRs and 25 982 UKRs) could be linked to HES records. We recorded signifi cant diff erences in several baseline variables (table 1) . On the basis of propensity score, 25 334 (98%) of 25 982 UKRs could be matched to TKRs. Because we matched on a ratio of three TKRs to each UKR, the matched study group consisted of 101 330 knees, of which 75 996 were TKRs. After matching, we achieved balance with respect to confounding factors (table 1) .
After matching, implant survival at 8 years (with allcause revision as the endpoint) was greater for TKR than for UKR (table 2, fi gure 1). Inclusion of all reoperations reduced overall survival values and attenuated the diff erence between TKR and UKR. At 8 years, implant survival (with revision/reoperation as the endpoint) was greater for TKR than for UKR (subhazard ratio 1·38, 95% CI 1·31-1·44; table 2). The survival hazard for reoperation varied with time. More reoperations were done for TKR than for UKR in the fi rst 3 months before the TKR hazard became shallower and the hazards crossed at around 15 months (fi gure 2). Therefore, a break was introduced at 3 months; in the fi rst 3 months, the revision/ reoperation rate was signifi cantly higher for TKR than for UKR; between 3 months and 8 years the risk of revision/ reoperation was signifi cantly higher for UKR than for TKR (table 2) .
Mortality was signifi cantly higher for TKR at all timepoints (table 2) . At 30 days, 90 of 76 074 patients (cumulative mortality rate 0·24%, 95% CI 0·19-0·29) had died in the TKR group compared with seven of 25 358 (0·06%, 0·03-0·12) in the UKR group. Hazard ratios were 0·23 (0·11-0·50) at 30 days and 0·47 (0·31-0·69) at 90 days. Although the hazard ratio fell with time, the absolute diff erence in death rates increased to 1·1% (0·7-1·4%) at 4 years, before decreasing to 0·7% (−0·5 to 1·9) at 8 years (fi gure 2).
Mean length of stay was 1·38 days shorter for UKR than for TKR (mean 5·52 [SD 3·97] for TKR; 4·14 [2·24] for UKR; 95% CI 1·33-1·43, p<0·0001) and readmission within the fi rst year was signifi cantly less likely in UKR than in TKR (incidence rate ratio 0·65, 0·58-0·72). Intraoperative complications, blood transfusion, thromboembolism, stroke, and myocardial infarction were signifi cantly less likely for UKR than for TKR (table 3) . Reasons for revision diff ered between TKR and UKR (table 4). Although aseptic loosening was the commonest reason for revision after either operation, signifi cantly more TKRs than UKRs were revised for infection and stiff ness. Progression of arthritis and bearing dislocation are modes of failure that were almost exclusive to UKR, and as a result, the odds ratio for revision for either reason greatly favoured TKR. Unexplained pain, aseptic loosening, malalignment, wear, periprosthetic fracture, and other unspecifi ed reasons for revision were signifi cantly more common in UKR than in TKR. The proportion of patients being revised for instability or implant fracture was much the same for the two operations (table 4) .
Although most revisions in TKR required augments or constrained implants, most of those recorded for UKR in the NJR were conversions to a primary TKR. These conversion-type operations accounted for the diff erence
Crude comparisons Propensity matched comparisons
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Intraoperative complications 0·70 (0·57-0·87) 0·001 0·73 (0·58-0·91) 0·006
Critical care admission 0·72 (0·60-0·86) <0·001 0·84 (0·69-1·02) 0·075
Blood transfusion 0·18 (0·12-0·26) <0·001 0·25 (0·17-0·37) <0·0001
Myocardial infarction 0·32 (0·20-0·52) <0·001 0·53 (0·31-0·90) 0·018
Odds ratios less than 1 favour unicompartmental knee replacement. in the revision rate between UKR and TKR. The probability of part revisions (including secondary patellar resurfacing in TKR, and bearing exchange in UKR) did not diff er between TKR and UKR, nor did they for complex revisions (table 5) .
Discussion
This study shows a signifi cantly higher risk of revision/ reoperation in patients undergoing UKR than for matched patients undergoing TKR. However, patients undergoing TKR are at increased risk of medical complications; they are twice as likely to have a venous thromboembolism, myocardial infarction, or deep infection, three times as likely to have a stroke, and four times as likely to need blood transfusions. As a result, these patients are four times more likely to die in the fi rst 30 days after surgery and about 15% more likely to die during the fi rst 8 years. Inpatient stays are longer, and readmissions are more likely after TKR than after UKR. Revisions of TKRs are more commonly due to stiff ness or infection, whereas revisions of UKR are more usually done for unexplained pain, arthritis progression, or other unspecifi ed reasons. Most revisions of UKR are conversions to a primary TKR, whereas most revisions of TKR are more complex procedures requiring larger components and increased levels of constraint-constrained implants introduce more tibiofemoral conformity to address the instability caused by the loss of the normal soft-tissue and bony constraints during revision knee surgery. Conversion-type operations accounted for all the diff erence in the revision rate between UKR and TKR. In patients with disease suitable for TKR or UKR, the decision of which procedure to off er should take into account the advantages and disadvantages of each, both in terms of functional results and of adverse outcomes. Although previous studies have examined functional outcomes, we have focused on adverse outcomes. 19, 20 In the short term, UKR has proved to have clear advantages, with reduced hospital stays, complications, readmissions, and mortality; however, it does have the disadvantage of an increased revision and reoperation rate. The diff erence in revisions largely consists of conversion-type operations, which are similar to a primary TKR. When off ered a choice of elective surgical procedures, patients are likely to rate mortality and major complications (such as myocardial infarction and stroke) as the worst possible outcomes. As such, these outcomes should be as, or more, important factors in the decision about which procedure to off er compared with the risk of reoperation/revision. Although revision is a deeply undesirable result after joint replacement, mortality after elective surgery is devastating.
Revision, reoperation, and death are uncommon outcomes of either procedure. At 4 years, the NNT to avoid a revision is 30 cases and to avoid a death is 93, whereas 8 years the NNT to avoid a revision is 18 cases and to avoid a death is 62. However, because knee replacement is very common, even small percentage diff erences aff ect large numbers of patients. Although estimates of the proportion of patients eligible for UKR vary (and have been estimated at up to 47% 10 ), a conservative estimate from a previous study 11 suggested that, at present, 21% of patients undergoing TKR meet the criteria for UKR. At 4 years, if 21% of the patients in the NHS currently undergoing TKR underwent UKR instead, a potential annual saving of 169 deaths, at the cost of 405 additional revisions, would result. However, as the revision rate of UKR tends to decrease with increasing surgeon volume, if these surgeons perform more UKRs per year, there might be fewer additional revisions. 21 The diff erence in revision rates between UKR and TKR has been well described (panel).
1,3,4 In this study, this diff erence is smaller than that shown in registry reports (which are unadjusted for patient characteristics) 3,4,11 and observational studies (which have varying degrees of adjustment). 23, 24 This diff erence suggests that patient selection for UKR or TKR exerts a powerful eff ect on ultimate revision rate. Inclusion of reoperations, which registries do not class as revisions, eff aces this eff ect further. Reasons for the residual diff erence are multifactorial and include the presence of additional failure mechanisms in UKR (mainly progression of disease), more subtle patient factors (such as the degree of cartilage damage before surgery), 30 and threshold for revision. UKR is easier to revise than TKR, and revision usually results in a primary TKR. As a result, UKR is fi ve times more likely to be revised than a TKR with the same patient-reported outcome. Diff erences in mortality between the two procedures have been previously reported; 28 however, as far as we are aware this study is the fi rst to confi rm this fi nding in matched patients and the fi rst to show an eff ect in the medium term. The reasons for the diff erences recorded have been discussed in the accompanying paper, 31 but the primary reason is likely to be that UKR surgery is less invasive, both for soft tissue and bone, than is TKR. 12, 32 Similar factors explain the fi ndings for perioperative morbidity. In addition to the short-term eff ect, this study shows that, although the eff ect of surgery on mortality is attenuated over time, an eff ect is seen into the medium term. Causality is more diffi cult to prove at longer followup times, but might be related to long-term consequences of complications of surgery, such as myocardial infarction, stroke, venous thromboembolism, or prosthetic joint infection, which we have shown to be more common in TKR than in UKR.
The strengths of this study include the use of an unselected registry sample, reducing the likelihood of sampling bias. The use of linked NJR/HES datasets allows adjustment for a very large set of potential confounders. The use of propensity score matching allows comparison of comparable cohorts and addresses the risk of confounding by indication. 16 This study is the most comprehensively matched study of these two treatments so far.
Weaknesses relate to the observational nature of the study. To address sources of bias, we matched the patients, which raises the possibility that some of the fi ndings, particularly diff erences in long-term mortality, could result from inadequate matching. If matching were inadequate, then the diff erence in mortality would be expected to progressively increase over time. However, although the survival curves for mortality diverge progressively for 4 years, they become parallel or converge slightly in the second half of the study, which is what would be expected because medical complications of surgery would only aff ect mortality for a limited time.
The matching process might also restrict the external validity of the study by excluding unmatchable patients. However, the crude diff erences between the groups were not large, and 25 329 (97·5%) of 25 982 UKRs could be matched to a TKR. This fi nding could be attributable to the fact that patients who are eligible for UKR could be off ered TKR or UKR, dependent on their surgeon's views, and suggests that the fi ndings shown here might be generalisable to the wider population of patients who are appropriate for UKR.
Propensity score matching has been used for more than 30 years and has gained popularity in diverse specialties of medicine, social sciences, and economics. 33, 34 In that time, the understanding of the strengths and limitations of propensity score matching has increased. 35 Although the aim of propensity score matching is to recreate the conditions of a randomised trial in an observational study, this can only be the case if all causes of confounding by indication are eliminated by the matching process (the principle of strong ignorability 33 ). In reality, all observational studies will have a degree of unmeasured confounding and the results of propensity score matched studies such as this must be interpreted with this in mind. 35 In this study, patients were matched for 20 variables, and the eff ect of a 21st, BMI, was examined after matching and shown not to aff ect outcome (appendix). Potential sources of unmeasured
Panel: Research in context
Systematic review
We searched Medline, Embase, and the Cochrane Library on July 31, 2013, to retrieve all studies comparing unicompartmental knee replacement (UKR) and total knee replacement (TKR) in terms of revision rate, mortality, or complications. Clinical trials and observational studies were included in the review. Additionally, the latest annual reports of six major NJRs (England and Wales, Australia, New Zealand, Sweden, Norway, and Denmark) and one large regional joint registry (Emilia-Romagna, Italy) were retrieved and interrogated. The search identifi ed two randomised trials, 20, 22 two retrospective cohort studies, 12, 23 and three casecontrol studies. [24] [25] [26] One retrospective study (examining patients with UKR in one knee and TKR in the other) was excluded from the review because it studied a design of UKR that has subsequently been withdrawn as a result of design factors leading to a high revision rate. 27 Only two randomised control trials comparing the two procedures exist. The fi rst, a study of 102 patients at 15 years, reported implant survival at 89·8% (95% CI 74·3-100) for UKR and 78·7% (56·2-100) for TKR, with better functional outcomes with UKR than with TKR. 20 However, substantial attrition was noted, with 45 (44%) of 102 knees in patients who died before 15 years. The second, of 104 knees at very early follow-up, reported better survival with TKR than with UKR at the cost of a higher rate of deep vein thrombosis and a greater fall in haemogolobin concentration with TKR. 22 All major joint registries show a higher revision rate for UKR than for TKR. Unmatched data from the NJR annual report shows hazard ratios between 2·9 and 3·7; 1 similar data from Australia show similar hazard ratios of 2·59 (95% CI 2·50-2·69) and from New Zealand of 2·72 (2·47-2·99).
3,4 Mortality in UKR and TKR has been little studied. The NJR 7th annual report shows hazard ratios of 0·36 (95% CI 0·22-0·58) at 90 days and 0·64 (0·58-0·72) at 5 years, adjusted for age, sex, and American Society of Anaesthesiologists' grade.
28 A large observational study of 2840 TKRs and UKRs adjusted for age, sex, body-mass index, and comorbidities showed signifi cantly increased rates of manipulation under anaesthesia (odds ratio 13, p<0·001), admission to critical care (7·4, p=0·049), and postoperative transfusion (8·5, p=0·036), and for complications overall (2·8, p<0·001). 12 In a smaller study, Lombardi and colleagues 26 reported a shorter length of stay (1·4 days for UKR vs 2·2 days for TKR, p<0·001); similar differences are reported in two other small studies. 25, 29 In Lyons and colleagues' 23 retrospective cohort study, reduced survival for UKR was reported with an institutional database (5606 TKRs and 279 UKRs, 10 year survival 95% for TKR, 90% for UKR), and in the small case-control study of Amin and colleagues. 24 
Interpretation
Our study is the most comprehensive comparison of UKR and TKR that has been done so far. The NJR is the largest joint replacement database in the world, and our study is the fi rst to address the problem of confounding by indication with propensity score techniques. Most previous comparisons of the two techniques have compared survival alone, and this is the fi rst study to compare TKR and UKR with such a wide selection of endpoints. This study has supported fi nding of a higher revision and revision/reoperation rate reported by earlier joint registery studies, but has also shown important advantages of UKR in terms of speed of recovery, rate of readmission, ease of revision, morbidity, and mortality. Patient-reported outcomes have not been examined in this study, but previous work has suggested that they could be better in TKR than in UKR. Future studies should examine patient-reported outcomes.
confounding include the radiological stage of disease (patients with only partial loss of cartilage thickness are more prone to revision than those with full-thickness cartilage defects 30 ); diff erences in complexity of operation (although cases with augmentation and those labelled as complex primaries are excluded, there might be more subtle diff erences between procedures); more detailed patient-level comorbidity data (although reliability of HES comorbidity data are well established 36, 37 ) , and level of preoperative activity. A randomised trial would be required to address these limitations; such a trial is in progress. 38 However, the primary outcomes of this trial are patient-reported outcome measures; the size of a randomised controlled trial that would be required to produce meaningful information about rarer outcomes such as mortality is prohibitive. Such questions are best answered with observational study designs.
The choice of which procedure to off er will depend on the individual patient. Decisions about treatment should be made on the basis of all outcome measures, not merely the revision rate of each procedure. This study should provide important evidence for making such decisions.
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